Generalized Myasthenia Gravis (gMG) is a condition where muscles become weak and tired quickly. This study is a long-term registry, which means it collects information about people with gMG who are using special medicines called Alexion C5 inhibitor therapies, like eculizumab (Soliris®) and ravulizumab (Ultomiris®). These medicines help manage symptoms of gMG.

The study will last up to 5 years. During this time, it will gather information about how well the medicines work and their safety. This is done by looking at medical records and asking patients about their health experiences. The data will be collected electronically.

• Participation is open to those diagnosed with gMG and currently using these therapies.
• Participants must agree to share their medical history and follow study rules.
• You cannot join if you’re part of another study for gMG therapy.

By joining, you contribute to understanding these treatments better, but remember, it doesn’t involve new treatment or compensation.